Semaglutide vs. Tirzepatide
Summary
Both are FDA-approved injectable incretin medications for type 2 diabetes and chronic weight management. Tirzepatide acts on two receptors (GIP and GLP-1); semaglutide acts on one (GLP-1). We do not state which is medically "best" — that depends on an individual's clinical picture.
At a glance
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Regulatory status | FDA-approved | FDA-approved |
| Dosing | Weekly injection (or daily oral Rybelsus) | Weekly injection |
| Approved for weight management | Yes (Wegovy) | Yes (Zepbound) |
| Also approved for | Cardiovascular risk reduction (Wegovy) | Obstructive sleep apnea with obesity (Zepbound) |
| Boxed warning | Thyroid C-cell tumors (rodent data) | Thyroid C-cell tumors (rodent data) |
Semaglutide
- Drug class
- GLP-1 receptor agonist
- Regulatory status
- FDA-approved
- Dosing
- Weekly injection (or daily oral Rybelsus)
- Approved for weight management
- Yes (Wegovy)
- Also approved for
- Cardiovascular risk reduction (Wegovy)
- Boxed warning
- Thyroid C-cell tumors (rodent data)
Tirzepatide
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Regulatory status
- FDA-approved
- Dosing
- Weekly injection
- Approved for weight management
- Yes (Zepbound)
- Also approved for
- Obstructive sleep apnea with obesity (Zepbound)
- Boxed warning
- Thyroid C-cell tumors (rodent data)
What they have in common
- Both are FDA-approved and available as brand-name products.
- Both slow gastric emptying and reduce appetite, with similar GI side effects.
- Both carry a boxed warning for thyroid C-cell tumors and share MEN 2 / medullary thyroid carcinoma contraindications.
- For both, weight tends to return after stopping without sustained lifestyle change.
Material differences
- Tirzepatide adds GIP activity to GLP-1 activity; semaglutide is GLP-1 only.
- Their secondary approved indications differ (cardiovascular risk vs. sleep apnea).
- Semaglutide offers a daily oral option (Rybelsus) for diabetes; tirzepatide is injection-only.
Decision considerations
- Which indication you are being treated for (diabetes, weight, cardiovascular risk, or sleep apnea).
- Whether an oral option matters to you.
- Insurance coverage and cost for the specific branded product.
- Your clinician's assessment of your medical history and contraindications.
Sources
- 1.WEGOVY (semaglutide) injection — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
- 2.ZEPBOUND (tirzepatide) injection — Prescribing Information — U.S. Food and Drug Administration. Government agencyAccessed July 24, 2026.
Last reviewed (yesterday)